Información del artículo
Texto completo
En el artículo “Prevención de la infección por rotavirus: directrices para el uso de la vacuna frente a rotavirus “ publicado en Pediatrics (Ed esp). 2007;63(1):41-51 se ha detectado un error de traducción en la página 43, 2ª columna . El párrafo «…Aunque el estudio incluyó a más de 68.000 niños, el número que recibió menos de 3 dosis de la vacuna o placebo fue inferior a 100. En este estudio la eficacia estimada de 1, 2 y 3 dosis de la vacuna fue del 29%, 80% y 95%, respectivamente» se sustituye por el siguiente:
«…Aunque el presente estudio incluyó a más de 68.000 niños, el número que recibió menos de tres dosis de vacuna o placebo fue inferior a 8.600. En un análisis que evaluó la eficacia de la vacuna empezando 14 días después de cada dosis y que incluyó los casos intercurrentes de gastroenteritis por rotavirus entre dosis, en este estudio, la disminución estimada de la tasa de hospitalizaciones y visitas al servicio de urgencias con 1, 2 y 3 dosis de vacuna fue del 83 %, 81 % y 95 %, respectivamente.
Bibliografía
[1]
New hope for people with sickle cell anemia [publicación n.o (FDA) 99-1251]. FDA Consumer. 1999 [consultado 15/12/2006]. Disponible en: www.fda.gov/fdac/features/496_sick.html
[2]
Maxwell K, Streetly A, Bevan D..
Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study..
BMJ, 318 (1999), pp. 1585-90
[3]
Platt OS, Brambilla DJ, Rosse WF, et al..
Mortality in sickle cell disease: life expectancy and risk factors for early death..
N Engl J Med, 330 (1994), pp. 1639-44
[4]
Bakanay SM, Dainer E, Clair B, et al..
Mortality in sickle cell patients on hydroxyurea therapy..
Blood, 105 (2005), pp. 545-7
[5]
Manci EA, Culberson DE, Yang YM, et al..
Causes of death in sickle cell disease: an autopsy study..
Br J Haematol, 123 (2003), pp. 359-65
[6]
Ross-Lee B, Kiss LE, Weiser MA..
Should health care reform be color-blind? Addressing the barriers to improving minority health..
J Am Osteopath Assoc, 94 (1994), pp. 664-71
[7]
Laurence B, George D, Woods D..
Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease..
J Natl Med Assoc, 98 (2006), pp. 365-9
[8]
Chua-Lim C, Moore RB, McCleary G, Shah A, Mankad VN..
Deficiencies in school readiness skills of children with sickle cell anemia: a preliminary report..
South Med J, 86 (1993), pp. 397-402
[9]
Gil KM, Carson JW, Porter LS, et al..
Daily stress and mood and their association with pain, health-care use, and school activity in adolescents with sickle cell disease..
J Pediatr Psychol, 28 (2003), pp. 363-73
[10]
Labbe E, Herbert D, Haynes J..
Physicians attitude and practices in sickle cell disease pain management [revisión en J Palliat Care. 2006;22:64]..
J Palliat Care, 21 (2005), pp. 246-51
[11]
Pack-Mabien A, Labbe E, Herbert D, Haynes J Jr..
Nurses attitudes and practices in sickle cell pain management..
Appl Nurs Res, 14 (1991), pp. 187-92
[12]
Shapiro BS, Benjamin LJ, Payne R, Heidrich G..
Sickle cellrelated pain: perceptions of medical practitioners..
J Pain Symptom Manage, 14 (1997), pp. 168-74
[13]
Linklater DR, Pemberton L, Taylor S, Zeger W..
Painful dilemmas: an evidence-based look at challenging clinical scenarios..
Emerg Med Clin North Am, 23 (2005), pp. 367-92
[14]
Brown RT, Connelly M, Rittle C, Clouse B..
A longitudinal examination predicting emergency room use in children with sickle cell disease and their caregivers..
J Pediatr Psychol, 31 (2006), pp. 163-73
[15]
About us [consultado 19/12/2006]. Disponible en: www.imconsortium.org/cahcim/about/home.html
[16]
Beider S..
An ethical argument for integrated palliative care..
Evid Based Complement Alternat Med, 2 (2005), pp. 227-31
[17]
Hill TP..
Freedom from pain:a matter of rights? Cancer Invest, 12 (1994), pp. 438-43
[18]
Weissman DE..
Cancer pain education for physicians in practice: establishing a new paradigm..
J Pain Symptom Manage, 12 (1996), pp. 364-71
[19]
Powers C, Szeto S, Pangtay D, Bort T, Cervi M, Cady R..
Evaluation of migraineurs preferences for naratriptan over conventional first-line agents..
Arch Fam Med, 9 (2000), pp. 753-7
[21]
Dinges DF, Whitehouse WG, Orne EC, et al..
Self-hypnosis training as an adjunctive treatment in the management of pain associated with sickle cell disease..
Int J Clin Exp Hypn, 45 (1997), pp. 417-32
[22]
gov. Hypnosis to manage pain and symptoms in patients with sickle cell disease [identificador NCT00 393250; consultado 15/12/2006]. Disponible en: www.clinicaltrials.gov/ct/gui/show/NCT00393250;jsessionid_6C45D5A45A665BD21F428E12C179EC77?order_7
[23]
Sodipo J..
Acupuncture and blood studies in sickle-cell anemia..
Am J Chin Med, 21 (1993), pp. 85-9
[24]
Myers C, Robinson M, Guthrie T Jr, Lamp S, Lottenberg R..
Adjunctive approaches for sickle cell chronic pain..
Complement Health Pract Rev, 5 (1999), pp. 203-12
[25]
American Academy of Pediatric.s, Committee on Bioethics and Committee on Hospital Care..
Palliative care for children..
Pediatrics, 106 (2000), pp. 351-7
[26]
Thomas VJ, Cohn T..
Communication skills and cultural awareness courses for healthcare professionals who care for patients with sickle cell disease..
J Adv Nurs, 53 (2006), pp. 480-8